Keiichi Nakahara

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

David Adams, Michael Polydefkis, Alejandra González‐Duarte et al. · The Lancet Neurology · 2020 · 156 citations

Medicine, Neurology, Pharmacotherapy +14

Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis

Masanori Nakagawa, Keiichi Nakahara, Yoshikazu Maruyama et al. · Journal of NeuroVirology · 1996 · 150 citations

Life Sciences, Hematology, Molecular Virology +4

Myopathy Induced by HMG–CoA Reductase Inhibitors in Rabbits: A Pathological, Electrophysiological, and Biochemical Study

Keiichi Nakahara, Masaru Kuriyama, Yoshito Sonoda et al. · Toxicology and Applied Pharmacology · 1998 · 119 citations

Medicine, Pathology, Pharmacology +8

A new type of hereditary motor and sensory neuropathy linked to chromosome 3

Hiroshi Takashima, Masanori Nakagawa, Keiichi Nakahara et al. · Annals of Neurology · 1997 · 85 citations

Life Sciences, Genetics, Neurology +17

Cytosolic Ca2+ Increase and Cell Damage in L6 Rat Myoblasts by HMG-CoA Reductase Inhibitors

Keiichi Nakahara, Toshihiko Yada, M Kuriyama et al. · Biochemical and Biophysical Research Communications · 1994 · 60 citations

Life Sciences, Biochemistry, Cell Biology +17